Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients

Lasse H Jakobsen, Fredrik Ellin, Knut B Smeland, Tove Wästerlid, Jacob H Christensen, Judit M Jørgensen, Pär L Josefsson, Andreas K Øvlisen, Harald Holte, Yngvild N Blaker, Jacob H Grauslund, Jon Bjørn, Daniel Molin, Ingemar Lagerlöf, Karin E Smedby, Katherine Colvin, Gita Thanarajasingam, Matthew J Maurer, Thomas M Habermann, Kevin W SongKatie Y Zhu, Alina S Gerrie, Chan Y Cheah, Tarec C El-Galaly

Publikation: Bidrag til tidsskriftArtikelForskningpeer review

Abstract

Non-endemic Burkitt lymphoma (BL) is a rare germinal centre B-cell-derived malignancy with the genetic hallmark of MYC gene translocation and with rapid tumour growth as a distinct clinical feature. To investigate treatment outcomes, loss of lifetime and relapse risk in adult BL patients treated with intensive immunochemotherapy, retrospective clinic-based and population-based lymphoma registries from six countries were used to identify 264 real-world patients. The median age was 47 years and the majority had advanced-stage disease and elevated LDH. Treatment protocols were R-CODOX-M/IVAC (47%), R-hyper-CVAD (16%), DA-EPOCH-R (11%), R-BFM/GMALL (25%) and other (2%) leading to an overall response rate of 89%. The two-year overall survival and event-free survival were 84% and 80% respectively. For patients in complete remission/unconfirmed, the two-year relapse risk was 6% but diminished to 0·6% for patients reaching 12 months of post-remission event-free survival (pEFS12). The loss of lifetime for pEFS12 patients was 0·4 (95% CI: -0·7 to 2) months. In conclusion, real-world outcomes of adult BL are excellent following intensive immunochemotherapy. For pEFS12 patients, the relapse risk was low and life expectancy similar to that of a general population, which is important information for developing meaningful follow-up strategies with increased focus on survivorship and less focus on routine disease surveillance.

OriginalsprogEngelsk
Sider (fra-til)661-671
Antal sider11
TidsskriftBritish Journal of Haematology
Vol/bind189
Udgave nummer4
Tidlig onlinedato4 feb. 2020
DOI
StatusUdgivet - maj 2020

Bibliografisk note

© 2020 British Society for Haematology and John Wiley & Sons Ltd.

Fingeraftryk

Udforsk hvilke forskningsemner 'Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients' indeholder.

Citationsformater